Literature DB >> 24224397

Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas.

Katherine B Puttgen1, Barbara Summerer, Jeremy Schneider, Bernard A Cohen, Emily F Boss, Nancy M Bauman.   

Abstract

OBJECTIVES: We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment.
METHODS: A retrospective cohort analysis was performed on 50 infants (age less than 12 months) with symptomatic infantile hemangiomas who were hospitalized for propranolol initiation between 2008 and 2012. Demographic data and disease characteristics were recorded. Systolic and diastolic blood pressures, heart rate, blood glucose values, and adverse events recorded during hospitalization were analyzed. An additional cohort of 200 consecutively treated children was also assessed for adverse events associated with outpatient propranolol use.
RESULTS: The median age among the inpatient cohort was 3.4 months (range, 0.8 to 12.0 months). Infants older than 6 months were more likely to exhibit bradycardia than were younger infants (p < 0.001). Hypotensive and/or bradycardic periods were infrequent and were not associated with observable clinical symptoms. The mean systolic and diastolic blood pressures and the mean heart rate decreased significantly from day 1 of hospitalization to day 2 (p = 0.004; p = 0.008; p < 0.001), but not from day 2 to day 3, when the propranolol dose was increased to target. Hypoglycemia was rare (0.3% incidence.) Among the 250 outpatients, 2 infants developed lethargy and hypoglycemia during a viral illness and recovered without sequelae. One infant experienced recurrent bronchospasm with viral illnesses and required concomitant bronchodilator therapy.
CONCLUSIONS: Frequent deviations from normal ranges of blood pressure and heart rate occur upon initiation of propranolol, but are clinically asymptomatic. These findings support that outpatient initiation of propranolol in healthy, normotensive infants appears to be a relatively safe alternative to inpatient initiation. Hypoglycemia is rare, but can occur throughout the treatment period; parent counseling is of paramount importance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24224397     DOI: 10.1177/000348941312200903

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  6 in total

Review 1.  Educational paper: therapy of infantile haemangioma--history and current state (part II).

Authors:  Sherief R Janmohamed; Gerard C Madern; Peter C J de Laat; Arnold P Oranje
Journal:  Eur J Pediatr       Date:  2014-09-03       Impact factor: 3.183

Review 2.  Treatment of infantile haemangiomas: recommendations of a European expert group.

Authors:  Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze
Journal:  Eur J Pediatr       Date:  2015-05-29       Impact factor: 3.183

3. 

Authors:  Imene Ben Jdidia; Kaouther Zribi; Meriam Boubaker; Amira Brahem; Mouna Sayadi; Marwa Tlijani; Zahra Saidani; Amani Cherif
Journal:  Can J Hosp Pharm       Date:  2021

4.  Severe hypoglycemia in propranolol treatment for infantile hemangiomas.

Authors:  Akira Morimoto; Michio Ozeki; Satoru Sasaki; Naoko Baba; Yoshihiro Kuwano; Tsuyoshi Kaneko
Journal:  Pediatr Int       Date:  2022-01       Impact factor: 1.617

5.  Medical Management of Vascular Anomalies.

Authors:  Reema Padia; Randall Bly; Catherine Bull; Amy E Geddis; Jonathan Perkins
Journal:  Curr Treat Options Pediatr       Date:  2018-04-27

Review 6.  Infantile Hemangioma: A Brief Review.

Authors:  Madalina Bota; Gheorghe Popa; Cristina Blag; Alexandru Tataru
Journal:  Clujul Med       Date:  2015-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.